NOME portfolio company Saga Diagnostics has reached a major milestone, as Roche has entered into a definitive agreement to acquire the company in a transaction valued at up to $ 595 million, including commercial and regulatory milestone payments. The transaction is subject to customary closing conditions and regulatory approvals and is expected to close by the third quarter of 2026.
Following completion of the transaction, Saga Diagnostics’ tumor‑informed molecular residual disease (MRD) platform, Pathlight™, is expected to be integrated into Foundation Medicine’s monitoring portfolio. Foundation Medicine is an independent affiliate of Roche and a global provider of precision oncology diagnostics.
Pathlight™ is a personalized, tumor‑informed MRD platform that combines whole genome sequencing (WGS) and digital PCR to identify and track structural variants, enabling ultra‑sensitive detection of minimal residual disease and cancer recurrence. The platform will support monitoring of treatment response and disease recurrence across multiple cancer types.
Pathlight™ is currently available in the United States and is covered by Medicare for cancer recurrence monitoring in early‑stage breast cancer across all subtypes, with plans for international availability.
Saga Diagnostics is part of the NOME portfolio and the announced acquisition represents a significant milestone in the company’s development and highlights the growing importance of MRD technologies in cancer diagnostics.